Search Result
Results for "
congestive
" in MedChemExpress (MCE) Product Catalog:
15
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-119515
-
|
(R)-(-)-Denopamine; TA-064
|
Adrenergic Receptor
|
Cardiovascular Disease
Cancer
|
|
Denopamine ((R)-(-)-Denopamine) is an orally active, selective β1-adrenergic agonist. Denopamine prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-α production in the heart. Cardiovascular effects .
|
-
-
- HY-119816
-
|
|
Others
|
Cardiovascular Disease
|
|
Piretanide is an oral active, relatively safe and effective diuretic. Piretanide has the potential for the research of congestive heart failure with a potential advantage of having potassium-sparing properties. Piretanide can also be used for the research of hypertension [1] [2].
|
-
-
- HY-123381
-
-
-
- HY-164430
-
|
BU-E-50
|
Histamine Receptor
|
Cardiovascular Disease
|
|
Arpromidine (BU-E-50) is the agonist for histamine H2 receptor and the antagonist for histamine H1 receptor. Arpromidine exhibits positive inotropic effect with less risks in causing arrhythmias. Arpromidine can be used in research of congestive heart failure .
|
-
-
- HY-B0592S
-
-
-
- HY-18347
-
|
YM 087 free base
|
Vasopressin Receptor
|
Cardiovascular Disease
|
|
Conivaptan (YM 087 free base) is antagonist for vasopressin V1A receptor and vasopressin V2 receptor. Conivaptan ameliorates congestive heart failure, improves cardiac systolic function .
|
-
-
- HY-106927
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
Bay Y5959 is a potent calcium channel agonist. Bay Y5959 binds to the DHP receptor in a voltage-dependent manner increases both the mean open time and the mean closed time of the Ca-channel. Bay Y5959 has the potential for the research of congestive heart failure, arrhythmic .
|
-
-
- HY-120521
-
-
-
- HY-137387
-
|
|
Drug Metabolite
|
Cardiovascular Disease
Others
|
|
Carvedilol Glucuronide is the metabolite of Carvedilol (HY-B0006). Carvedilol (BM 14190) is an antagonist for β/α-1 adrenergic receptor. Carvedilol inhibits lipid peroxidation with an IC50 of 5 μM. Carvedilol is an antihypertensive agent with potential use in angina and congestive heart failure. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome .
|
-
-
- HY-120577
-
|
|
Others
|
Cardiovascular Disease
|
|
BA 41899 is a purely calcium-sensitizing agent. BA 41899 is completely devoid of phosphodiesterase (PDE) III inhibitory activity or any other known inotropic mechanism. BA 41899 can be used for the research of cardiovascular diseases, such as congestive heart failure (CHF) .
|
-
-
- HY-153168
-
|
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
Bemoradan (compound 10a) is an orally active and selective canine Phosphodiesterase (PDE) fraction III inhibitor. Bemoradan is a long-acting, potent, inotropic vasodilator and a novel cardiotonic agent, and can be used in congestive heart
failure research .
|
-
-
- HY-119816R
-
|
|
Others
|
Cardiovascular Disease
|
|
Piretanide (Standard) is the analytical standard of Piretanide. This product is intended for research and analytical applications. Piretanide is an oral active, relatively safe and effective diuretic. Piretanide has the potential for the research of congestive heart failure with a potential advantage of having potassium-sparing properties. Piretanide can also be used for the research of hypertension .
|
-
-
- HY-B0368
-
Captopril
Maximum Cited Publications
16 Publications Verification
SQ 14225
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Cancer
|
|
Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
-
- HY-B0368A
-
|
SQ 14225 hydrochloride
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Cancer
|
|
Captopril (SQ 14225) hydrochloride, antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril hydrochloride is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
-
- HY-156863
-
-
-
- HY-B0368R
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Cancer
|
|
Captopril (Standard) is the analytical standard of Captopril. This product is intended for research and analytical applications. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
-
- HY-B0006A
-
|
BM 14190 phosphate hemihydrate
|
Adrenergic Receptor
Autophagy
Bacterial
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) is a non-selective β/α-1 blocker . Carvedilol phosphate hemihydrate inhibits lipid peroxidation with an IC50 of 5 μM. Carvedilol phosphate hemihydrate is a multiple action antihypertensive agent with potential use in angina and congestive heart failure . Carvedilol phosphate hemihydrate is an autophagy inducer that inhibits the NLRP3 inflammasome .
|
-
-
- HY-117715
-
|
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
CK-3197 is a weak inhibitor of Peak lll cyclic 3'5'-adenosine monophosphate phosphodiesterase
(CAMP PDEl). CK-3197 has hemodynamic and myocardial energetic effects in vivo. CK-3197 is an imidazolone derivative used as a selective positive inotropic agent for congestive heart failure .
|
-
-
- HY-135065
-
|
|
Trace Amine-associated Receptor (TAAR)
|
Metabolic Disease
|
|
3-Iodothyronamine (hydrochloride) is an endogenous and rapid-acting derivative of thyroid hormone. 3-Iodothyronamine potently activates an orphan G protein-coupled receptor in vitro (TAAR1) and induced hypothermia in vivo on a rapid time scale. 3-Iodothyronamine can be used for the research of congestive heart failure .
|
-
-
- HY-B0006
-
-
-
- HY-P3678
-
|
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Neuropeptide Y (18-36) (porcine) is a competitive neuropeptide Y (NPY) cardiac receptor antagonist. Neuropeptide Y (18-36) (porcine) inhibits the binding of I-NPY to cardiac ventricular membranes in a concentration-dependent manner with an IC50 value of 158 nM and an Ki value of 140 nM. Neuropeptide Y (18-36) (porcine) can be used for the research of congestive heart failure .
|
-
-
- HY-B0203
-
|
R 065824
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Nebivolol (R 065824) is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
|
-
-
- HY-B0203A
-
|
R 065824 hydrochloride
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
|
-
-
- HY-B0592
-
|
RU44570
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
|
-
-
- HY-B0592A
-
|
RU44570 hydrochloride
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Trandolapril (RU44570) hydrochloride is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolapril hydrochlorideat. Trandolapril hydrochloride is an orally active angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
|
-
-
- HY-U00209
-
|
Benfurodil; CB4091; Eudilat
|
Others
|
Cardiovascular Disease
|
|
Benzofurodil is a cardiotonic, which is used for the chronic treatment of congestive heart failure.
|
-
-
- HY-B0592R
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Trandolapril (Standard) is the analytical standard of Trandolapril. This product is intended for research and analytical applications. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
|
-
-
- HY-A0043
-
-
-
- HY-A0043A
-
-
-
- HY-A0043B
-
-
-
- HY-B0209
-
-
-
- HY-14286
-
-
-
- HY-18207
-
-
-
- HY-18206
-
-
-
- HY-100239
-
-
-
- HY-18206A
-
-
-
- HY-B0932
-
|
L-Propionylcarnitine chloride; ST-261
|
Others
|
Others
|
|
Levocarnitine propionate hydrochloride (L-Propionylcarnitine chloride; ST-261) is used to treat the deterioration of renal function, congestive heart failure, intermittent claudication, and other diseases.
|
-
-
- HY-B2081A
-
|
W-2900A hydrochloride
|
Others
|
Cardiovascular Disease
Metabolic Disease
|
|
Etozolin hydrochloride is a diuretic agent. Etozolin hydrochloride inhibits fluid and electrolyte reabsorption in the loop of Henle. Etozolin hydrochloride can be used in research of congestive heart failure, hypertension and edema .
|
-
-
- HY-B0209S
-
|
SR-720-22-d7
|
Thrombin
|
Cardiovascular Disease
|
|
Metolazone-d7 is deuterium labeled Metolazone. Metolazone (SR-720-22) is primarily used to treat congestive heart failure and high blood pressure.
|
-
-
- HY-18206S
-
-
-
- HY-W050000
-
-
-
- HY-106045A
-
|
CI 914
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
Imazodan hydrochloride is the hydrochloride form of Imazodan (HY-106045). Imazodan hydrochloride is a selective inhibitor for phosphodiesterase III (PDE III), which increases myocardial contractility by blocking the cAMP degradation, and improves the contractile function of heart. Imazodan hydrochloride serves also as a peripheral vasodilator .
|
-
-
- HY-106045
-
|
CI 914 free base
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
Imazodan is a selective inhibitor for phosphodiesterase III (PDE III), which increases myocardial contractility by blocking the cAMP degradation, and improves the contractile function of heart. Imazodan serves also as a peripheral vasodilator .
|
-
-
- HY-14286R
-
-
-
- HY-B2081
-
|
W-2900A
|
Others
|
Cardiovascular Disease
Metabolic Disease
|
|
Etozolin (W-2900A) is a diuretic agent. Etozolin inhibits fluid and electrolyte reabsorption in the loop of Henle. Etozolin can be used in research of congestive heart failure, hypertension and edema .
|
-
-
- HY-B0209R
-
|
SR-720-22 (Standard)
|
Thrombin
|
Cardiovascular Disease
|
|
Metolazone (Standard) is the analytical standard of Metolazone. This product is intended for research and analytical applications. Metolazone (SR-720-22) is primarily used to treat congestive heart failure and high blood pressure.
|
-
-
- HY-B0384
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Temocapril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
|
-
-
- HY-100713
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
|
-
-
- HY-113702
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
PD 113413 is formed by subsequent hydrolysis of the diketopiperazine quinapril analog. PD 113413 is a potent angiotensin-converting enzyme inhibitor. PD 113413 can be used for research of hypertension and congestive heart failure .
|
-
-
- HY-W414915
-
|
CGP 48933 methyl ester
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Valsartan methyl ester (Compound 3) is a derivative of Valsartan (HY-18204). Valsartan methyl ester is an orally active antagonist for angiotensin II, that inhibits angiotensin II (IC50 of 0.06 μM), angiotensin II-induced pressor response in rabbit aorta (IC50 of 0.068 μM) and angiotensin II-induced pressor response in the pithed rat model (10% inhibition at 10 mg/kg, p.o.) .
|
-
- HY-W414915R
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Valsartan methyl ester (Standard) is the analytical standard of Valsartan methyl ester. This product is intended for research and analytical applications. Valsartan methyl ester (Compound 3) is a derivative of Valsartan (HY-18204). Valsartan methyl ester is an orally active antagonist for angiotensin II, that inhibits angiotensin II (IC50 of 0.06 μM), angiotensin II-induced pressor response in rabbit aorta (IC50 of 0.068 μM) and angiotensin II-induced pressor response in the pithed rat model (10% inhibition at 10 mg/kg, p.o.) .
|
-
- HY-B0932S1
-
|
L-Propionylcarnitine-d5 (chloride); ST-261-d5
|
Isotope-Labeled Compounds
|
Others
|
|
Levocarnitine propionate-d5 (hydrochloride) is the deuterium labeled Levocarnitine propionate hydrochloride. Levocarnitine propionate hydrochloride (L-Propionylcarnitine chloride; ST-261) is used to treat the deterioration of renal function, congestive heart failure, intermittent claudication, and other diseases.
|
-
- HY-117281S
-
-
- HY-B0932S
-
|
L-Propionylcarnitine-d3 (chloride); ST-261-d3
|
Isotope-Labeled Compounds
|
Others
|
|
Levocarnitine propionate-d3 (hydrochloride) is the deuterium labeled Levocarnitine propionate hydrochloride. Levocarnitine propionate hydrochloride (L-Propionylcarnitine chloride; ST-261) is used to treat the deterioration of renal function, congestive heart failure, intermittent claudication, and other diseases.
|
-
- HY-18206AR
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Cancer
|
|
Lisinopril (dihydrate) (Standard) is the analytical standard of Lisinopril (dihydrate). This product is intended for research and analytical applications. Lisinopri dihydrate (MK-521 dihydrate) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.
|
-
- HY-B0932S2
-
|
L-Propionylcarnitine-d9 chloride
|
Isotope-Labeled Compounds
Others
|
Others
|
|
Levocarnitine propionate-d9 (hydrochloride) (L-Propionylcarnitine-d9 (chloride)) is deuterium labeled Levocarnitine propionate (hydrochloride). Levocarnitine propionate hydrochloride (L-Propionylcarnitine chloride) is used to study diseases such as renal function deterioration, congestive heart failure, and intermittent claudication .
|
-
- HY-100713S
-
-
- HY-18344
-
|
SR 121463
|
Vasopressin Receptor
|
Metabolic Disease
|
|
Satavaptan (SR 121463) is an antagonist for vasopressin V2 receptor. Satavaptan regulates the vasopressin regulated phosphopeptides and vasopressin-mediated signaling pathway. Satavaptan is potential in ameliorating hyponatremia .
|
-
- HY-A0230A
-
|
SCH 33844 hydrochloride
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Spirapril (SCH 33844) hydrochloride is a potent angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active proagent of Spiraprilat and can be used for the research of hypertension, congestive heart failure .
|
-
- HY-A0230
-
|
SCH 33844
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Spirapril is a potent and cross the blood-brain barrier angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active proagent of Spiraprilat and can be used for the research of hypertension, congestive heart failure .
|
-
- HY-A0154
-
|
Deacetyllanatoside C; Desacetyllanatoside C
|
Na+/K+ ATPase
Drug Metabolite
|
Cardiovascular Disease
|
|
Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations .
|
-
- HY-106973A
-
|
CHF 1035
|
Dopamine Receptor
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Nolomirole (CHF 1035) hydrochloride is an orally active and selective DA2 dopaminergic receptor/α2-adrenoceptor agonist. Nolomirole attenuates the heart failure signs in the Monocrotaline (HY-N0750)-induced congestive heart failure model. Nolomirole increases cardiac output .
|
-
- HY-B1030
-
|
|
Flavivirus
Dengue virus
Autophagy
Enterovirus
|
Cardiovascular Disease
Cancer
|
|
Lanatoside C is a cardiac glycoside, can be used in the treatment of congestive heart failure and cardiac arrhythmia.Lanatoside C has an IC50 of 0.19 μM for dengue virus infection in HuH-7 cells. Lanatoside C can effectively inhibit all four serotypes of dengue virus, flavivirus Kunjin, alphavirus Chikungunya, Sindbis virus and the human enterovirus 71 .
|
-
- HY-15718B
-
|
PST2744 oxalate
|
Na+/K+ ATPase
|
Cardiovascular Disease
|
|
Istaroxime oxalate (PST2744 oxalate) is the oxalate form of Istaroxime (HY-15718). Istaroxime oxalate is is an inotropic agent, that inhibits Na +/K +-ATPase with an IC50 of 0.11 μM. Istaroxime oxalate increases force of contraction in guinea pig atria and twitch amplitude in isolated guinea pig myocytes without causing lethal arrhythmias .
|
-
- HY-A0154R
-
|
|
Na+/K+ ATPase
Drug Metabolite
|
Cardiovascular Disease
|
|
Deslanoside (Standard) is the analytical standard of Deslanoside. This product is intended for research and analytical applications. Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations .
|
-
- HY-B0592S2
-
|
rac-RU44570-d5
|
Isotope-Labeled Compounds
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
rac-Trandolapril-d5 (rac-RU44570-d5) is deuterium labeled Trandolapril. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
|
-
- HY-B0006S
-
|
|
Adrenergic Receptor
Autophagy
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Carvedilol-d3 is the deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker[1]. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure[2]. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome[3].
|
-
- HY-B0006S1
-
|
BM 14190-d4
|
Adrenergic Receptor
Autophagy
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Carvedilol-d4 is the deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker[1]. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure[2]. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome[3].
|
-
- HY-B0006S2
-
-
- HY-B0006R
-
|
BM 14190 (Standard)
|
Adrenergic Receptor
Autophagy
Bacterial
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Carvedilol (Standard) is the analytical standard of Carvedilol. This product is intended for research and analytical applications. Carvedilol (BM 14190) is a non-selective β/α-1 blocker . Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure . Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome .
|
-
- HY-19263
-
|
|
Endothelin Receptor
|
Cardiovascular Disease
|
|
BMS-193884 is a selective, orally active, and competitive ETA antagonist with 10000-fold greater affinity for the human ETA receptor (Ki=1.4 nM) than for the ETB receptor .
|
-
- HY-B0135
-
|
|
NKCC
GABA Receptor
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Furosemide is a potent and orally active inhibitor of Na +/K +/2Cl -?(NKCC) cotransporter, NKCC1 and NKCC2 .?Furosemide is also a GABAA?receptors antagonist and displays 100-fold selectivity for?α6-containing receptors than?α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .
|
-
- HY-B0135A
-
|
|
NKCC
GABA Receptor
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Furosemide sodium is a potent and orally active inhibitor of Na +/K +/2Cl - (NKCC) cotransporter, NKCC1 and NKCC2 . Furosemide sodium is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide sodium acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .
|
-
- HY-B0203AR
-
|
R 065824 hydrochloride (Standard)
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Nebivolol (hydrochloride) (Standard) is the analytical standard of Nebivolol (hydrochloride). This product is intended for research and analytical applications. Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
|
-
- HY-B1030R
-
|
|
Dengue virus
Flavivirus
Autophagy
Enterovirus
|
Cardiovascular Disease
Cancer
|
|
Lanatoside C (Standard) is the analytical standard of Lanatoside C. This product is intended for research and analytical applications. Lanatoside C is a cardiac glycoside, can be used in the treatment of congestive heart failure and cardiac arrhythmia.Lanatoside C has an IC50 of 0.19 μM for dengue virus infection in HuH-7 cells. Lanatoside C can effectively inhibit all four serotypes of dengue virus, flavivirus Kunjin, alphavirus Chikungunya, Sindbis virus and the human enterovirus 71 .
|
-
- HY-18346
-
|
OPC-31260
|
Vasopressin Receptor
|
Cardiovascular Disease
Metabolic Disease
Endocrinology
Cancer
|
|
Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
|
-
- HY-123593
-
|
OPC-31260 hydrochloride
|
Vasopressin Receptor
|
Cardiovascular Disease
Metabolic Disease
Endocrinology
Cancer
|
|
Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
|
-
- HY-B1639
-
|
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC50 of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits PDE4 inhibitory effect with an IC50 of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects .
|
-
- HY-B0368S
-
|
SQ 14225-d3
|
Isotope-Labeled Compounds
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Captopril-d3 is deuterium labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM[1][2][3].
|
-
- HY-117181
-
|
|
Phosphodiesterase (PDE)
Adrenergic Receptor
|
Cardiovascular Disease
|
|
UK-1745 is a cardiotonic agent with vasodilating and antiarrhythmic properties. It increases intracellular levels of cyclic adenosine monophosphate (cAMP) in cardiomyocytes by inhibiting phosphodiesterase III, thereby enhancing myocardial contractility. Additionally, UK-1745 exhibits β-adrenergic receptor blocking activity, which helps reduce the oxygen consumption of the heart and prevent calcium overload. These characteristics make UK-1745 a promising candidate for research in congestive heart failure .
|
-
- HY-B0135S
-
|
|
NKCC
GABA Receptor
|
Metabolic Disease
Cancer
|
|
Furosemide-d5 is the deuterium labeled Furosemide. Furosemide is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC) cotransporter, NKCC1 and NKCC2[1]. Furosemide is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema[2].
|
-
- HY-B0135R
-
|
|
NKCC
GABA Receptor
|
Metabolic Disease
Cancer
|
|
Furosemide (Standard) is the analytical standard of Furosemide. This product is intended for research and analytical applications. Furosemide is a potent and orally active inhibitor of Na +/K +/2Cl - (NKCC) cotransporter, NKCC1 and NKCC2 . Furosemide is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .
|
-
- HY-10965
-
|
KW-3902
|
Adenosine Receptor
|
Neurological Disease
|
|
Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment.
Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450) .
Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases .
|
-
- HY-18346S
-
|
OPC-31260-d6
|
Isotope-Labeled Compounds
Vasopressin Receptor
|
Metabolic Disease
Endocrinology
Cancer
|
|
Mozavaptan-d6 (OPC-31260-d6) is the deuterium labeled Mozavaptan. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
|
-
- HY-136677
-
|
|
Others
|
Cardiovascular Disease
|
|
LND 796 is an aminosteroidal derivative with positive inotropic effects similar to those of digitalis. It exhibits electrophysiological, toxic, and inotropic effects in normal and partially potassium-depolarized ventricular muscles. LND 796 requires higher concentrations than digoxin to induce the same toxic symptoms. It exhibits a concentration-dependent positive inotropic effect on guinea pig papillary muscles in normal potassium solution. In partially potassium-depolarized papillary muscles, LND 796 enhances both components of contraction and increases the amplitude of slow action potentials. The mechanism of positive inotropic action of LND 796 involves enhanced calcium entry in calcium channels and inhibition of sodium-potassium ATPase. Due to its expanded positive inotropic range, LND 796 may have potential application in the treatment of congestive heart failure.
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3678
-
|
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Neuropeptide Y (18-36) (porcine) is a competitive neuropeptide Y (NPY) cardiac receptor antagonist. Neuropeptide Y (18-36) (porcine) inhibits the binding of I-NPY to cardiac ventricular membranes in a concentration-dependent manner with an IC50 value of 158 nM and an Ki value of 140 nM. Neuropeptide Y (18-36) (porcine) can be used for the research of congestive heart failure .
|
-
- HY-120521
-
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0209S
-
|
|
|
Metolazone-d7 is deuterium labeled Metolazone. Metolazone (SR-720-22) is primarily used to treat congestive heart failure and high blood pressure.
|
-
-
- HY-18206S
-
|
|
|
Lisinopril-d5 is the deuterium labeled Lisinopril. Lisinopril (MK-521) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.
|
-
-
- HY-B0932S
-
|
|
|
Levocarnitine propionate-d3 (hydrochloride) is the deuterium labeled Levocarnitine propionate hydrochloride. Levocarnitine propionate hydrochloride (L-Propionylcarnitine chloride; ST-261) is used to treat the deterioration of renal function, congestive heart failure, intermittent claudication, and other diseases.
|
-
-
- HY-B0592S
-
|
|
|
Trandolapril-d5 is a deuterium labeled Trandolapril (RU44570). Trandolapril is an orally active angiotensin converting enzyme (ACE) inhibitor for hypertension and congestive heart failure (CHF)[1].
|
-
-
- HY-B0932S1
-
|
|
|
Levocarnitine propionate-d5 (hydrochloride) is the deuterium labeled Levocarnitine propionate hydrochloride. Levocarnitine propionate hydrochloride (L-Propionylcarnitine chloride; ST-261) is used to treat the deterioration of renal function, congestive heart failure, intermittent claudication, and other diseases.
|
-
-
- HY-117281S
-
|
|
|
Moexipril-d5 is the deuterium labeled Moexipril. Moexipril hydrochloride is a potent orally active non-sulfhydryl angiotensin converting enzyme(ACE) inhibitor, which is used for the treatment of hypertension and congestive heart failure[1][2].
|
-
-
- HY-B0932S2
-
|
|
|
Levocarnitine propionate-d9 (hydrochloride) (L-Propionylcarnitine-d9 (chloride)) is deuterium labeled Levocarnitine propionate (hydrochloride). Levocarnitine propionate hydrochloride (L-Propionylcarnitine chloride) is used to study diseases such as renal function deterioration, congestive heart failure, and intermittent claudication .
|
-
-
- HY-100713S
-
|
|
|
Temocapril-d5 is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases[1][2].
|
-
-
- HY-B0592S2
-
|
|
|
rac-Trandolapril-d5 (rac-RU44570-d5) is deuterium labeled Trandolapril. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
|
-
-
- HY-B0006S
-
|
|
|
Carvedilol-d3 is the deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker[1]. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure[2]. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome[3].
|
-
-
- HY-B0006S1
-
|
|
|
Carvedilol-d4 is the deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker[1]. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure[2]. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome[3].
|
-
-
- HY-B0006S2
-
|
|
|
Carvedilol-d5 is deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker[1]. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure[2]. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome[3].
|
-
-
- HY-B0368S
-
|
|
|
Captopril-d3 is deuterium labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM[1][2][3].
|
-
-
- HY-B0135S
-
|
|
|
Furosemide-d5 is the deuterium labeled Furosemide. Furosemide is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC) cotransporter, NKCC1 and NKCC2[1]. Furosemide is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema[2].
|
-
-
- HY-18346S
-
|
|
|
Mozavaptan-d6 (OPC-31260-d6) is the deuterium labeled Mozavaptan. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
